First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease

  • Oncologist. 2019 Mar;24(3):303-e102. doi: 10.1634/theoncologist.2018-0707.
Shawn Patrick Zinnen  1 ,  Alexander Karpeisky  2 ,  Daniel D Von Hoff  3 ,  Larisa Plekhova  4 ,  Alexander Alexandrov  5
Affiliations
  • 1. MBC Pharma Inc., Aurora, Colorado, USA [email protected].
  • 2. MBC Pharma Inc., Aurora, Colorado, USA.
  • 3. Translational Genomics Research Institute (TGEN), Phoenix, Arizona, USA.
  • 4. Osteros Biomedica Ltd., Moscow, Russia.
  • 5. Maxwell Biotech Group, Moscow, Russia.
PMID: 30413669 DOI: 10.1634/theoncologist.2018-0707
Products